$22.80
+4.30%Price chart
Aug 12Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8Sep 11
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.0x
Market Cap
$2.73B
MomentumView details →
1D Return
+4.30%
YTD Return
−38.07%
RSI (14)
24.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.0x
Market Cap
$2.73B
RSI (14)
24.6
MomentumView details →
1D Return
+4.30%
YTD Return
−38.07%
SummaryUpdated Jun 1, 2026
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Naarden, the Netherlands. The company went public in February 2021 and focuses on developing innovative treatments for metabolic diseases, particularly cardiovascular conditions related to cholesterol management. NewAmsterdam's primary focus is advancing its lead drug candidate through clinical trials to address unmet medical needs in cholesterol treatment and cardiovascular disease prevention.
Similar companies
Latest newsMore news →
NewAmsterdam Pharma Co N.V. appointed Robert W. Gunning as principal accounting officer, Vice President and Controller, effective August 10, 2026, succeeding Louise Kooij who will depart on August 31, 2026.30d agoNewAmsterdam Pharma reported Q2 2026 revenue of $3.7 million, down 80.6% year-over-year, and a net loss of $64.1 million.39d agoNewAmsterdam Pharma Co N.V. elected John W. Smither and Janneke van der Kamp as non-executive directors, effective June 2, 2026.102d ago